{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:14Z","timestamp":1790706134696,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaip.2025.11.038","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:39:13Z","timestamp":1770284353000},"page":"361-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond"],"prefix":"10.1016","volume":"14","author":[{"given":"Florence Ida","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-7667","authenticated-orcid":false,"given":"Krishan D.","family":"Chhiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbjit S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.11.038_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.11.038_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jaip.2018.03.007","article-title":"How to approach chronic inducible urticaria","volume":"6","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaip.2023.11.029","article-title":"Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights","volume":"12","author":"Kovalkova","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","article-title":"Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis","volume":"81","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.11.038_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2024.1487831","article-title":"Key differences between chronic inducible and spontaneous urticaria","volume":"5","author":"Bizjak","year":"2024","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib7","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.jaip.2023.08.020","article-title":"Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment-results from CURE","volume":"11","author":"Buttgereit","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib8","first-page":"12","article-title":"Prevalence of concomitant angioedema in chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"41","author":"Weerasubpong","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib9","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jaip.2021.03.038","article-title":"A comparative study of sex distribution, autoimmunity, blood, and inflammatory parameters in chronic spontaneous urticaria with angioedema and chronic histaminergic angioedema","volume":"9","author":"Sabate-Bresco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2016.11.037","article-title":"chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures","volume":"5","author":"Doong","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib11","series-title":"A survey on prognosis of acute urticaria on 1075 patients in ten clinics in Hiroshima","author":"Kamigaki","year":"2024"},{"key":"10.1016\/j.jaip.2025.11.038_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2017.07.012","article-title":"Recurrence of chronic urticaria: incidence and associated factors","volume":"6","author":"Kim","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA(2)LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.11.038_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40413-018-0193-4","article-title":"Management of chronic spontaneous urticaria: a worldwide perspective","volume":"11","author":"Kolkhir","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.11.038_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13601-017-0141-3","article-title":"Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria","volume":"7","author":"van den Elzen","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaip.2014.12.007","article-title":"Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria","volume":"3","author":"Amin","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib18","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1111\/all.14412","article-title":"IgM and IgA in addition to IgG autoantibodies against FcvarepsilonRIalpha are frequent and associated with disease markers of chronic spontaneous urticaria","volume":"75","author":"Altrichter","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cei.13428","article-title":"Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria","volume":"200","author":"Asero","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib21","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib22","article-title":"Emerging IgE and non-IgE targeted therapies for chronic urticaria","author":"Chhiba","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib23","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2500\/aap.2011.32.3483","article-title":"Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria","volume":"32","author":"Magen","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.11.038_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab induced reductions in mast cell FceRI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaip.2025.11.038_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.038_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jaip.2019.10.018","article-title":"High-dose omalizumab use in patients with chronic spontaneous urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl 5","key":"10.1016\/j.jaip.2025.11.038_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.13697","article-title":"Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria","volume":"30","author":"Gimenez-Arnau","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.11.038_bib35","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaip.2015.11.025","article-title":"Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria","volume":"4","author":"Palacios","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil Fc\u03b5RI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2025.11.038_bib41","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jaci.2021.02.038","article-title":"The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes","volume":"147","author":"Johal","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib42","article-title":"Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria","volume":"4","author":"Cain","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2025.11.038_bib43","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome","volume":"12","author":"Russo","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.jaip.2025.11.038_bib44","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.jaip.2024.05.043","article-title":"Characteristics of patients with chronic spontaneous urticaria who are late-responders to omalizumab","volume":"12","author":"Mosnaim","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2024.12.645","article-title":"Biopredictors for omalizumab response in patients with chronic spontaneous urticaria","author":"Le","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib46","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","article-title":"Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring","volume":"10","author":"Kocaturk","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2025.06.004","article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis","volume":"156","author":"Chu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.11.038_bib50","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/all.16446","article-title":"CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study","volume":"80","author":"Saini","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib51","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bjp.0707002","article-title":"Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506","volume":"150","author":"Harrison","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaip.2025.11.038_bib53","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2025.11.038_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2025.11.038_bib55","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2025.05.030","article-title":"Current and future landscape of Bruton tyrosine kinase inhibitors in allergy","volume":"156","author":"Lin","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib56","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.038_bib57","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","article-title":"Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial","volume":"27","author":"Metz","year":"2021","journal-title":"Nat Med"},{"issue":"Suppl","key":"10.1016\/j.jaip.2025.11.038_bib58","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.anai.2022.08.594","article-title":"Remibrutinib improves chronic spontaneous urticaria in patients with low or high ige","volume":"129","author":"Hayama","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib59","doi-asserted-by":"crossref","first-page":"AB369","DOI":"10.1016\/j.jaci.2023.11.883","article-title":"Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies","volume":"153","author":"Mosnaim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl","key":"10.1016\/j.jaip.2025.11.038_bib60","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.anai.2022.08.537","article-title":"Remibrutinib improves chronic spontaneous urticaria in patients irrespective of CU-index: results from phase 2b study","volume":"129","author":"Carr","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib62","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.anai.2024.08.317","article-title":"No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria","volume":"133","author":"Palumbo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib63","series-title":"ACTRIMS congress [poster], West Palm Beach","author":"Tillmann","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial","volume":"161","author":"Gimenez-Arnau","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.11.038_bib65","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bcp.14923","article-title":"Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a\/b randomised double-blind placebo-controlled study","volume":"87","author":"Dickson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2025.11.038_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib67","series-title":"Presented at European Academy of Dermatology and Venereology (EADV) Congress, Amsterdam","article-title":"Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with chronic spontaneous urticaria","author":"Maurer","year":"2024"},{"key":"10.1016\/j.jaip.2025.11.038_bib68","series-title":"Sustained disease control following withdrawal of barzolvolimab in patients with chronic spontaneous urticaria","author":"Gim\u00e9nez-Arnau","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib69","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib70","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.11.038_bib71","series-title":"Celldex Therapeutics Investor Relations","article-title":"Celldex therapeutics announces positive topline results from barzolvolimab phase 2 study in chronic spontaneous urticaria [press release]","year":"2023"},{"key":"10.1016\/j.jaip.2025.11.038_bib72","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1242\/dev.113.2.689","article-title":"Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function","volume":"113","author":"Yoshinaga","year":"1991","journal-title":"Development"},{"key":"10.1016\/j.jaip.2025.11.038_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.215","article-title":"BLU-808, a potent and selective small molecule inhibitor of wild-type c-KIT for mast cell disorders","volume":"153","author":"Grassian","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib74","series-title":"Jasper Therapeutics reports positive data from BEACON study of briquilimab in chronic spontaneous urticaria [press release]","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib75","series-title":"Jasper Therapeutics reports clinical data update from briquilimab studies in chronic spontaneous urticaria [press release]","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib76","series-title":"Presented at European Academy of Dermatology and Venereology (EADV) Congress, Paris, France","article-title":"EVO756, an oral MRGPRX2 inhibitor, demonstrates robust treatment effect in chronic inducible urticaria (LBA-260)","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib77","article-title":"Siglecs as potential targets of therapy in human mast cell- and\/or eosinophil-associated diseases","volume":"69","author":"O'Sullivan","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib78","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib79","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.10.005","article-title":"Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C)","volume":"133","author":"Casale","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib81","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jaip.2025.06.014","article-title":"Exploring mepolizumab use in chronic spontaneous urticaria: an open-label, single-arm, exploratory study","volume":"13","author":"Phillipps","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.11.038_bib82","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.11.038_bib83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.11.038_bib84","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","article-title":"Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study","volume":"155","author":"McLaren","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib85","doi-asserted-by":"crossref","first-page":"AB372","DOI":"10.1016\/j.jaci.2023.11.891","article-title":"Efficacy and safety of TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamine: results from a phase \u2160b study","volume":"153","author":"Lu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.11.038_bib86","series-title":"Povorcitinib demonstrates rapid improvement in hives and itch in patients with chronic spontaneous urticaria (CSU)","author":"Soong","year":"2025"},{"key":"10.1016\/j.jaip.2025.11.038_bib87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/bjd\/ljae342","article-title":"A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council","volume":"192","author":"Haag","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:36:04Z","timestamp":1780126564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825011444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2213219825011444"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.038","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}